Liquid Biopsy Solutions for Research Biomarker Discovery

Why Liquid Biopsy Matters for Researchers

For many research projects, traditional tissue biopsies create limitations: they are invasive, represent only a single point in time, and often fail to capture the full heterogeneity of a disease. Liquid biopsy offers a research-driven alternative, allowing scientists to investigate circulating molecules in a non-invasive and repeatable way.

By analyzing cell-free nucleic acids (cfNA) such as cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), exosomal RNA (exRNA), and circulating nucleosomes, researchers can study disease biology in real time, without the constraints of solid tissue sampling. These molecular traces carry valuable information that extends far beyond genetic mutations:

• Epigenetic regulation – cfDNA methylation and histone modifications reveal early regulatory changes before structural mutations occur.
• Intercellular communication – exosomes and their RNA cargo provide stable signatures of cell signaling and immune modulation.
• Dynamic disease monitoring – serial sampling enables tracking of treatment response, therapy resistance, and minimal residual disease.
• Tissue-of-origin insights – cfDNA fragment patterns and methylation profiles help identify the source of circulating nucleic acids.

With the resolution of next-generation sequencing (NGS), liquid biopsy transforms static snapshots into dynamic molecular timelines, giving researchers the ability to explore biomarker discovery, early detection, and mechanistic studies with unprecedented clarity.

Our Core Technologies: Multi-Omics Liquid Biopsy Approaches

Technical Workflow & Quality Considerations

Our liquid biopsy workflows are optimized to maximize sensitivity while preserving data quality from challenging low-input samples. Each step incorporates strict quality control to ensure reproducibility and minimize background noise.

Sample Handling

• Accepted inputs: plasma, serum, urine, or isolated exosome fractions.
• Stabilization protocols protect cfDNA fragments and exosomal RNA integrity during transport and processing.

Extraction & Library Preparation

• Optimized methods for recovering short cfDNA (~160–180 bp) and low-abundance exRNA.
• Isolation workflows enrich vesicle-derived RNA while reducing contaminants such as rRNA.
• Library preparation strategies tailored for low-input cfDNA or exRNA.

Sequencing & Assays

• High-depth NGS to capture rare events with robust coverage.
• Compatible with cfChIP-seq, HEBER-seq, and Targeted EM-seq assays.
• Strict contamination controls applied to minimize background signals.

Quality Control Metrics

• cfDNA fragment size distribution to confirm nucleosomal peaks.
• exRNA integrity and transcript diversity checks.
• Library complexity and duplication rate tracking.
• Conversion efficiency assessment for EM-seq.
• Sequencing QC: mapping efficiency, coverage uniformity, and reproducibility across replicates.

By combining optimized protocols with rigorous QC, CD Genomics ensures that liquid biopsy data are reliable, sensitive, and publication-ready, supporting studies in biomarker discovery, minimal residual disease, and tissue-of-origin inference.

Bioinformatics & Data Interpretation

Generating high-quality sequencing data is only the first step. The real value lies in performing comprehensive liquid biopsy analysis to transform millions of reads into biologically meaningful insights. At CD Genomics, our bioinformatics team provides end-to-end analytical support tailored to liquid biopsy research.

Core strengths of our bioinformatics capabilities:

• Comprehensive pipelines – from raw NGS data processing, alignment, and QC to advanced statistical modeling and integrative multi-omics analysis.
• Sensitive signal detection – optimized algorithms for identifying low-frequency cfDNA variants, subtle methylation shifts, and rare exRNA transcripts, while controlling background noise.
• Epigenetic and regulatory insights – correlation of cfDNA fragmentomics, nucleosome positioning, and methylation states with transcriptional activity and tissue-of-origin signatures.
• Biomarker discovery and validation – robust frameworks for detecting reproducible biomarker panels, assessing cohort-level variability, and generating classifier models for early detection and minimal residual disease studies.
• Multi-layer integration – ability to combine cfDNA, exosomal RNA, and epigenetic datasets into unified reports that reveal regulatory networks and intercellular communication pathways.
• Publication-ready outputs – clear visualizations including heatmaps, volcano plots, Circos diagrams, and correlation matrices, accompanied by standardized data formats (FASTQ, BAM, VCF, expression tables).

With rigorous pipelines, validated tools, and domain expertise, we deliver researcher-ready results that empower new discoveries in epigenetics, liquid biopsy sequencing, translational research, and biomarker science..

Use Cases / Research Scenarios

Liquid biopsy research has become a versatile research tool, providing dynamic access to molecular signatures in blood and other body fluids. Below are representative scenarios where our solutions bring unique value.

Why Choose CD Genomics

Choosing the right partner for liquid biopsy research is critical when working with scarce and delicate materials such as cfDNA and exosomal RNA. At CD Genomics, we focus on providing data that researchers can trust, with workflows optimized for sensitivity, reproducibility, and interpretability.

Our advantages:

• High sensitivity, low background – Optimized extraction, library preparation, and NGS protocols detect rare cfDNA fragments and subtle methylation changes while minimizing noise.
• Low-input compatibility – Validated workflows handle limited plasma or serum volumes without compromising coverage or quality.
• Multi-omics integration – Combined analysis of cfDNA fragmentomics, histone modifications, exRNA expression, and methylation supports comprehensive biomarker discovery.
• Transparent deliverables – Every project includes raw sequencing data, processed results, QC metrics, and publication-ready visualizations.
• Proven reliability – Our platforms are grounded in peer-reviewed methodologies and benchmarked for reproducibility across replicates and cohorts.
• Customizable design – Assay panels, histone marks, and CpG targets can be tailored to specific research questions.

With CD Genomics, researchers gain more than sequencing services—they gain a partner dedicated to advancing biomarker discovery, early detection, minimal residual disease tracking, and tissue-of-origin research with rigor and transparency.

Getting Started

Engaging with CD Genomics is designed to be straightforward and collaborative. We support researchers from project planning through data delivery, ensuring that each study is tailored to specific scientific goals.

How to begin your project:

1. Discuss your research goals

Contact our team to outline your objectives, whether they involve biomarker discovery, epigenetics, minimal residual disease, or tissue-of-origin studies.

2. Sample submission

Provide plasma, serum, or exosome preparations following our submission guidelines. We will assist with requirements for volume, concentration, and storage conditions to ensure optimal cfDNA and exRNA integrity.

3. Choose your assays

Select from cfChIP-seq, HEBER-seq, Targeted EM-seq, or an integrated multi-omics approach. Customized targets (histone marks, CpG panels, or exRNA classes) can be included upon request.

4. Sequencing & analysis

Your samples undergo rigorous QC, library preparation, and NGS assays, followed by comprehensive bioinformatics to generate interpretable results.

5. Receive high-quality outputs

Deliverables include raw data files, processed results, QC reports, and publication-ready visualizations—enabling direct integration into your research workflows.

FAQ / Key Questions Researchers Ask

• Q: Are these services strictly for research only?
  • • A: Yes. All assays and workflows are intended for research use only, not for diagnostic or clinical decision-making.
• Q: What sample types are accepted, and what are the storage requirements?
  • • A: We accept plasma, serum, urine, or exosome-enriched fractions as input. Samples should be collected in EDTA or specialized stabilization tubes, processed or frozen promptly to avoid nucleic acid degradation. Proper storage at −80 °C and avoiding repeated freeze-thaw cycles help maintain integrity of cfDNA, exRNA, and methylation signals.
• Q: What kinds of bioinformatics outputs and visualizations will I receive?
  • • A: Deliverables typically include raw sequencing files (FASTQ/BAM), processed data matrices (expression, methylation, fragment sizes), QC reports, and visualization plots such as heatmaps, volcano plots, Circos diagrams, and clustering or PCA plots. All data formats are suitable for downstream publication or further statistical analysis.
• Q: Can custom targets, histone marks, or CpG panels be included?
  • • A: Yes. Customization is supported. Researchers can propose specific histone modifications, CpG loci, or exRNA classes as targets. Panel design is refined in the consultation phase to align with your hypotheses or cohort study requirements.
• Q: What are realistic turnaround expectations?
  • • A: Turnaround depends on the scope (number of samples, degree of panel customization, depth of sequencing). During project planning we'll provide a timeline estimate based on your assay choices (cfChIP-seq, HEBER-seq, Targeted EM-seq or combined). Though the time isn't fixed here, we aim for clear communication so you can plan experiments and publication schedules accordingly.

Call to Action & Disclaimer

Ready to accelerate your liquid biopsy research? Partner with CD Genomics to access advanced sequencing-based assays for cfDNA, exRNA, and methylation profiling. Whether your focus is biomarker discovery, early detection, minimal residual disease, or tissue-of-origin studies, our integrated solutions deliver the sensitivity and reproducibility your work requires.

Next steps:

• [Request a Quote] – Receive a tailored plan for your project.
• [Start a Pilot Project] – Test our workflows with a small sample set before scaling up.
• [Discuss Your Project] – Connect with our experts to refine assay design and analysis goals.

Disclaimer

All services are provided strictly for research use only. They are not intended for diagnostic or clinical applications.